AARC Honors: Joyner Receives 2026 Jimmy A. Young Award - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

AARC Recognition: Robert L. Joyner Jr. Awarded the 2026 Jimmy A. Young Honor

  • By

  • Lisa Weisenberger

  • October 5, 2026

Share

Clinical Scorecard: AARC Recognition: Robert L. Joyner Jr. Awarded the 2026 Jimmy A. Young Honor

At a Glance

CategoryDetail
ConditionRespiratory Care
Key MechanismsCuriosity, collaboration, and continued learning in the field.
Target PopulationPatients requiring respiratory care, particularly in pediatric medicine.
Care SettingClinical and research environments in respiratory care.

Key Highlights

  • Robert L. Joyner, Jr. awarded the 2026 Jimmy A. Young Award.
  • Recognition for contributions to respiratory care.
  • Career development from CRT trainee to leadership.
  • Emphasis on patient care and research.
  • Focus on pediatric medicine.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients in need of respiratory care services.

          Insights drawn from extensive experience in patient care and research.

          Clinical Best Practices

          • Promote curiosity and collaboration in respiratory care.
          • Encourage continued learning among healthcare professionals.

          Related Resources & Content

            Original Source(s)

            AARC Honors: Joyner Receives 2026 Jimmy A. Young Award

            • by Lisa Weisenberger

            • October 5, 2026

            Related Content

            Interpreting viral severe acute respiratory infection in critically ill immunocompromised patients: phenotype, co-infections, and severity

            Non-invasive respiratory supports in ARDS: Physiology-guided use, pitfalls, and pathways to success

            FDA updates PAH label with trial data

            In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.